949934-31-0

Basic information

• Product Name: (3-chlorophenyl){4-[(N-tert-butoxycarbonylpiperazin-4-yl)methyl]phenyl}methanone
• Synonyms: (3-chlorophenyl){4-[(N-tert-butoxycarbonylpiperazin-4-yl)methyl]phenyl}methanone
• CAS NO: 949934-31-0
• Molecular Weight: 414.932
• Mol File: 949934-31-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (3-chlorophenyl){4-[(N-tert-butoxycarbonylpiperazin-4-yl)methyl]phenyl}methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (3-chlorophenyl){4-[(N-tert-butoxycarbonylpiperazin-4-yl)methyl]phenyl}methanone(949934-31-0)
• EPA Substance Registry System: (3-chlorophenyl){4-[(N-tert-butoxycarbonylpiperazin-4-yl)methyl]phenyl}methanone(949934-31-0)

Safety Data

• Hazardous Substances Data: 949934-31-0(Hazardous Substances Data)

Upstream product

• 587-04-2 m-Chlorobenzaldehyde 
• 13395-60-3 (3-chlorophenyl)(4-methylphenyl)methanone 
• 106-38-7 para-bromotoluene 
• 945657-22-7 (4-bromomethyl-phenyl)(3-chloro-phenyl)methanone 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1014987-03-1 tert-butyl 4-(4-((3-chlorophenyl)(1H-imidazol-1-yl)methyl)benzyl)piperazine-1-carboxylate 
• 949934-34-3 C₂₃H₂₈Cl₂N₂O₂*ClH 
• 949934-32-1 (3-chlorophenyl){4-[(N-tert-butoxycarbonylpiperazin-4-yl)methyl]phenyl}methanol 

Relevant articles and documents

Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: Further structure-activity relationships, in vivo studies, and preliminary toxicity profiling

Despite recent progress in the fight against malaria, the emergence and spread of drug-resistant parasites remains a serious obstacle to the treatment of infections. We recently reported the development of a novel antimalarial drug that combines the 4-aminoquinoline pharmacophore of chloroquine with that of clotrimazole-based antimalarials. Here we describe the optimization of this class of hybrid drug through in-depth structure-activity relationship studies. Antiplasmodial properties and mode of action were characterized in vitro and in vivo, and interactions with the parasites 'chloroquine resistance transporter' were investigated in a Xenopus laevis oocyte expression system. These tests indicated that piperazine derivatives 4b and 4d may be suitable for coadministration with chloroquine against chloroquine-resistant parasites. The potential for metabolism of the drugs by cytochrome P450 was determined in silico, and the lead compounds were tested for toxicity and mutagenicity. A preliminary pharmacokinetic analysis undertaken in mice indicated that compound 4b has an optimal half-life.

ANTIMALARIAL AGENTS HAVING POLYAROMATIC STRUCTURE

Antimalarial agents having a novel pharmacophore of formula (I) are herein described. These polycyclic compounds are able to inhibit chloroquine-sensitive and chloroquine-resistant strains ofPlasmodium falciparum (Pf). Furthermore, the synthesis of these compounds involves few steps from commercial products with low cost of production.Λa présente invention concerne des agents antimalariaux comportant un nouveau pharmacophore de formule (I). Ces composés polycycliques sont susceptibles d''inhiber les souches sensibles à la chloroquine et résistantes à la chloroquine de Plasmodium falciparum (Pf). En outre, la synthèse de ces composés est peu onéreuse et implique peu d''étapes à partir des produits commerciaux.